FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
Project Oncology® - Un pódcast de ReachMD
Categorías:
FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer. Released July 28, 2017
